[A23-26] Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V
Last updated 05.10.2023
Project no.:
A23-26
Commission:
Commission awarded on 30.03.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adults with unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin
Indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-69 | Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-87 | Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-31 | Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-27 | Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-83 | Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26 | Commission completed |
| A23-138 | Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
10-05-2023 A G-BA decision was published.
G-BA documents on this decision